MEDICINOVA INC
Close on Oct 19, 2026
- Market cap
- $68.91M
- P/E (TTM)
- –
- Dividend yield
- –
About Medicinova
Pharmaceutical Preparations, SIC 2834
MediciNova, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious medical conditions with unmet needs, primarily targeting the United States commercial market. Its research and development efforts center on two principal product candidates: MN-166 (ibudilast) and MN-001 (tipelukast). MN-166 is an oral anti-inflammatory and neuroprotective agent being investigated for neurological and respiratory indications, including progressive multiple sclerosis, amyotrophic lateral sclerosis, degenerative cervical myelopathy, glioblastoma, and the prevention of acute respiratory distress syndrome. MN-001 is evaluated for fibrotic and metabolic conditions, including nonalcoholic fatty liver disease and hypertriglyceridemia. The company engages with trial participants and works alongside research institutions, government entities, and corporate partners.
The company conducts clinical trials, research collaborations, and lease operations across the United States, Canada, the United Kingdom, and Japan. MediciNova maintains its principal executive headquarters in La Jolla, California.
Summary of the business section of Medicinova's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MEDICINOVA INC
- Headquarters
- La Jolla, CA
- Address
- 4275 Executive Square, Suite 300 92037
- Phone
- (858) 373-1500
- Website
- medicinova.com
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Diego, California
Stock & identifiers
- Ticker
- MNOV
- Exchange
- Nasdaq
- IPO date
- Dec 8, 2006
- Shares outstanding
- 49M, Aug 11, 2026
- Public float
- $62.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1226616
- CUSIP
- 58468P206
- ISIN
- US58468P2065
- EIN
- 33-0927979
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yuichi Iwaki | President and CEO | 1,091,933 |
| Kazuko Matsuda | Chief Medical Officer | 322,996 |
| Hideki Nagao | Director | 0 |
| Carolyn Beaver | Director | – |
| Nicole Lemerond | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Yuichi Iwaki | $1.76M | $1.34M | $735.62K | $64 | – |
| FY2024 Dr. Yuichi Iwaki | $1.41M | $1.61M | $424.60K | $102 | – |
| FY2023 Dr. Yuichi Iwaki | $1.39M | $1.15M | $846.68K | $73 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We have six employees as of the date of this report, all of which are full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 22, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 2, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 7, 2013 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 7, 2011 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 22, 2009 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 5, 2009 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 17, 2009 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 16, 2009 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 5, 2006 | Listing | Registration of securities on an exchange (Form 8-A) |